BVF INC IL's Q3 2026 13F: 4 new positions, 1 exit
Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 47 reported positions · accession 0000921895-26-003162
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | XOMA ROYALTY CORPORATION (XOMA) | 8.3% | — | −8.3 pts | −7.59M sh | −100% |
| Reduced | REVOLUTION MEDICINES INC (RVMD) | 14.2% | 16.6% | +2.4 pts | −505K sh | −17% |
| Reduced | DISC MEDICINE INC (IRON) | 2.2% | 0.5% | −1.7 pts | −920K sh | −80% |
| Increased | TYRA BIOSCIENCES INC (TYRA) | 1.2% | 3.0% | +1.8 pts | +2.74M sh | +186% |
| Reduced | MIRUM PHARMACEUTICALS INC (MIRM) | 3.2% | 1.1% | −2.0 pts | −649K sh | −61% |
| Increased | ENTERA BIO LTD (ENTX) | 0.1% | 1.6% | +1.5 pts | +14.63M sh | +603% |
| Increased | ALKERMES PLC (ALKS) | 2.9% | 3.8% | +0.9 pts | +692K sh | +32% |
| Increased | STOKE THERAPEUTICS INC (STOK) | 2.1% | 3.1% | +1.0 pts | +1.06M sh | +42% |
| New | PYXIS ONCOLOGY INC (PYXS) | — | 0.9% | +0.9 pts | +11.83M sh | new |
| Reduced | XENCOR INC (XNCR) | 2.9% | 5.1% | +2.2 pts | −907K sh | −13% |
| Reduced | STRUCTURE THERAPEUTICS INC (GPCR) | 4.6% | 2.8% | −1.9 pts | −675K sh | −20% |
| Reduced | KURA ONCOLOGY INC (KURA) | 2.4% | 2.4% | 0.0 pts | −1.76M sh | −21% |
| New | ALECTOR INC (ALEC) | — | 0.6% | +0.6 pts | +10.05M sh | new |
| Reduced | AVALO THERAPEUTICS INC (AVTX) | 1.0% | 0.5% | −0.5 pts | −1.17M sh | −56% |
| Reduced | NEKTAR THERAPEUTICS (NKTR) | 4.3% | 4.2% | 0.0 pts | −257K sh | −11% |
| Increased | SAGIMET BIOSCIENCES INC (SGMT) | 0.5% | 1.1% | +0.6 pts | +1M sh | +40% |
| Reduced | PALVELLA THERAPEUTICS INC NE (PVLA) | 2.6% | 2.8% | +0.1 pts | −65,640 sh | −10% |
| New | TCGX ACQUISITION CORP (TCGX) | — | 0.2% | +0.2 pts | +500K sh | new |
| New | RESEARCH ALLIANCE CORP IV (RACD) | — | 0.2% | +0.2 pts | +500K sh | new |
| Increased | CRESCENT BIOPHARMA INC. (CBIO) | 1.3% | 1.5% | +0.2 pts | +345K sh | +13% |
| Reduced | ZYMEWORKS INC (ZYME) | 2.4% | 3.0% | +0.6 pts | −185K sh | −5% |
| Increased | ONKURE THERAPEUTICS INC (OKUR) | 0.4% | 0.4% | 0.0 pts | +810K sh | +25% |
| Reduced | MONTE ROSA THERAPEUTICS INC (GLUE) | 2.8% | 1.7% | −1.1 pts | −184K sh | −4% |
| Reduced | IMMUNOCORE HLDGS PLC (IMCR) | 1.1% | 1.2% | +0.2 pts | −63,554 sh | −5% |
| Reduced | X4 PHARMACEUTICALS INC (XFOR) | 0.3% | 0.2% | −0.1 pts | −657K sh | −29% |
| Reduced | ANNEXON INC (ANNX) | 1.3% | 1.2% | −0.1 pts | −420K sh | −5% |
| Reduced | TENAX THERAPEUTICS INC (TENX) | 0.1% | 0.0% | −0.1 pts | −315K sh | −93% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 66.0% of the equity book
Changes in the top 10 this quarter: STOK entered · TYRA entered · ZYME entered · XOMA left · GPCR left · MIRM left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC (RVMD) | 14.2% | 16.6% | |
| 2 | KYMERA THERAPEUTICS INC (KYMR) | 11.4% | 14.2% | |
| 3 | GH RESEARCH PLC (GHRS) | 5.9% | 6.7% | |
| 4 | MOONLAKE IMMUNOTHERAPEUTICS (MLTX) | 8.0% | 6.2% | |
| 5 | XENCOR INC (XNCR) | 2.9% | 5.1% | |
| 6 | NEKTAR THERAPEUTICS (NKTR) | 4.3% | 4.2% | |
| 7 | ALKERMES PLC (ALKS) | 2.9% | 3.8% | |
| 8 | STOKE THERAPEUTICS INC (STOK) | 2.1% | 3.1% | Entered the top 10 |
| 9 | TYRA BIOSCIENCES INC (TYRA) | 1.2% | 3.0% | Entered the top 10 |
| 10 | ZYMEWORKS INC (ZYME) | 2.4% | 3.0% | Entered the top 10 |
| — | XOMA ROYALTY CORPORATION (XOMA) | 8.3% | 0.0% | Left the top 10 |
| — | STRUCTURE THERAPEUTICS INC (GPCR) | 4.6% | 2.8% | Left the top 10 |
| — | MIRUM PHARMACEUTICALS INC (MIRM) | 3.2% | 1.1% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).